Creatv MicroTech

What Creatv MicroTech does

Creatv MicroTech, Inc. is a privately held US biotechnology company founded in 1996 and headquartered in Potomac, Maryland, operating a small team of 1-10 employees. Through its Creatv Bio division, the company develops and commercializes the LifeTracDx® liquid biopsy blood test, a blood-based cancer diagnostic built on the detection of two proprietary cellular biomarkers: Cancer Associated Macrophage-Like Cells (CAMLs, 25-300 µm), which the company reports are present across all cancer stages and in more than 30 cancer types, and Circulating Tumor Cells (CTCs, 8-25 µm), which are detected in breast, prostate, colorectal, and small cell lung cancers and used for therapy response and PD-L1 expression monitoring. The platform supports cancer screening, residual disease and recurrence detection, aggressiveness determination, patient stratification, companion diagnostics, and the delivery of high-quality DNA for sequencing, without requiring a tissue sample.

Creatv Bio's commercial model is B2B services-led, targeting pharmaceutical companies and healthcare providers. The BioPharma Services offering positions LifeTracDx® as a translational and biomarker tool for clinical trials, drug development, and patient stratification, with direct engagement of enterprise pharmaceutical sponsors as the primary channel. The company's June 2026 strategic partnership with Neovia Oncology to study multiple drug resistance in solid tumors using LifeTracDx® for the NEV-801 program illustrates how the platform is deployed in translational pharma collaborations. Scientific credibility is reinforced through an active publication pipeline spanning journals, posters, and training videos, while distribution is described as global in scope. Pricing is not publicly disclosed and revenue is not reported, consistent with a sub-scale, privately funded operation that has historically relied on a single disclosed non-dilutive grant of $625,000 from the Congressionally Directed Medical Research Programs in 2018.

Name

Creatv MicroTech

Legal name

Creatv MicroTech, Inc.

Website

https://creatvmicrotech.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1–10 employees

Short description

Creatv MicroTech, through its Creatv Bio division, develops the LifeTracDx® liquid biopsy blood test that detects Cancer Associated Macrophage-Like Cells and Circulating Tumor Cells to support early cancer detection, therapy monitoring, and BioPharma clinical trial services for pharmaceutical sponsors and healthcare providers.

Ownership category

akta.pro rank

Product category

Liquid Biopsy Cancer Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Liquid biopsy diagnostics
• Cancer blood testing
• Companion diagnostics services
• Circulating tumor cells
• Oncology biopharma services

Headquarters

HQ city

Potomac

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels2 records

Core offering

Creatv MicroTech, through its Creatv Bio division, provides the LifeTracDx® liquid biopsy blood test that detects Cancer Associated Macrophage-Like Cells (CAMLs, 25-300 µm) and Circulating Tumor Cells (CTCs, 8-25 µm) for early cancer detection, diagnosis, recurrence monitoring, therapy response assessment, and companion diagnostics. The platform supports clinical use cases across more than 30 cancer types and supplies BioPharma services for patient stratification, treatment response monitoring, and high-quality DNA delivery for sequencing in drug development and clinical trials.

Product overview

Creatv Bio, a division of Creatv MicroTech, offers a unified liquid biopsy platform comprising three integrated products: LifeTracDx® (the primary blood test), CAMLs detection (Cancer Associated Macrophage-Like Cells), and CTCs detection (Circulating Tumor Cells). Together, these products enable early cancer detection, diagnosis, recurrence monitoring, therapy response assessment, and companion diagnostics—all through blood-based testing without requiring tissue samples. The platform also provides BioPharma Services supporting drug development and clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• LifeTracDx®: Liquid biopsy blood test used for patient stratification and treatment response monitoring in cancer therapy.

Products and services

• LifeTracDx® Liquid Biopsy Blood Test
• CAMLs (Cancer Associated Macrophage-Like Cells) Detection Service
• CTCs (Circulating Tumor Cells) Detection Service
• BioPharma Services for Oncology Drug Development and Clinical Trials

Quantifiable outcome

• CAMLs detected in more than 30 types of cancer
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Neovia Oncology LLCcoreStrategic or Co-development Partner · 2 June 2026Strategic partnership to study multiple drug resistance (MDR) in solid tumors, focusing on Neovia's NEV-801 drug candidate for advanced cancer patients in late lines of therapy. The collaboration uses Creatv's LifeTracDx® liquid biopsy blood test to generate translational and biomarker data for patient stratification and treatment response monitoring. Neovia is also exploring broader platform applications for NEV-801 in next-generation oncology, including antibody-drug conjugate strategies.

Recent moves4 records

Expansion highlights3 records

Direct peers

• Guardant Health: Guardant Health is a leading liquid biopsy company offering ctDNA-based blood tests for cancer detection and monitoring (Guardant360, Shield). It is the most established direct competitor in oncology liquid biopsy, and Creatv Bio's LifeTracDx® competes in the same clinical workflow with a CAMLs-based alternative biology.
• GRAIL: GRAIL's Galleri test is a multi-cancer early detection (MCED) blood test targeting screening in healthy and at-risk populations. Creatv Bio's pan-cancer, all-stage CAMLs platform targets the same early-detection opportunity using a different biomarker class.
• Menarini Silicon Biosystems: Menarini Silicon Biosystems produces the CellSearch system, the only FDA-cleared CTC-based test for metastatic breast, prostate, and colorectal cancers. It is a direct peer in the CTC detection space, particularly in late-stage cancer monitoring.
• Natera: Natera's Signatera test is a leading tumor-informed ctDNA MRD/monitoring assay used in clinical trials and patient monitoring. Creatv Bio competes directly in the same residual disease detection, recurrence monitoring, and treatment response use cases that Natera targets.
• ANGLE plc: ANGLE plc has developed the Parsortix system for CTC harvest from blood, used in cancer research and clinical trial applications. It competes with Creatv Bio's CTCs detection arm in pharma services and CTC-based therapy monitoring.
• Epic Sciences: Epic Sciences develops liquid biopsy tests based on circulating tumor cell (CTC) analysis for therapy selection and monitoring. It is a direct comparable to Creatv Bio's CTCs detection product, both targeting pharma-sponsored clinical trials and therapy monitoring in advanced cancers.

Broad incumbents

• Foundation Medicine: Foundation Medicine (a Roche subsidiary) offers comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). It is a broad incumbent in the precision oncology space that overlaps with Creatv Bio's companion diagnostics and BioPharma services offerings.
• Exact Sciences: Exact Sciences is a major cancer diagnostics company (Cologuard, Oncotype DX) with a broad screening and treatment-selection portfolio. While its primary platform is stool-based screening, it is a leading incumbent competing for the same oncology diagnostics market that Creatv Bio's liquid biopsy addresses.
• Bio-Techne: Bio-Techne is a diversified life sciences tools company with diagnostics and proteomics offerings (including ExoDx prostate test). It is a broad incumbent with overlapping capabilities in liquid biopsy biomarkers and clinical diagnostics services.

Emerging players

• RareCyte: RareCyte develops instrumentation and consumables for rare cell detection, including CTCs, from blood. As a smaller, more specialized player, it overlaps with Creatv Bio's CTC and rare-cell detection capabilities, particularly in pharma and translational research use cases.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Creatv MicroTech